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Assessing relevant molecular differences between human-induced pluripotent stem cells (hiPSCs)
andhumanembryonicstemcells(hESCs)isimportant,giventhatsuchdifferencesmayimpacttheir
potential therapeutic use. Controversy surrounds recent gene expression studies comparing hiPSCs
and hESCs. Here, we present an in-depth quantitative mass spectrometry-based analysis of hESCs,
two different hiPSCs and their precursor ﬁbroblast cell lines. Our comparisons conﬁrmed the high
similarity of hESCs and hiPSCS at the proteome level as 97.8% of the proteins were found
unchanged. Nevertheless, a small group of 58 proteins, mainly related to metabolism, antigen
processing and cell adhesion, was found signiﬁcantly differentially expressed between hiPSCs and
hESCs. A comparison of the regulated proteins with previously published transcriptomic studies
showed a low overlap, highlighting the emerging notion that differences between both pluripotent
cell lines rather reﬂect experimental conditions than a recurrent molecular signature.
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Introduction
Human embryonic stem cells (hESCs) are capable of self-
renewal and multi-lineage differentiation (i.e., pluripotency;
Thomson et al, 1998). Owing to these two unique properties,
they are considered as one of the most promising sources for
tissue replacement therapies. However, the use of hESCs
entails numerous ethical issues as they are derived from
human embryos. Recently, reprogramming of somatic cells to
an embryonic stem cell-like state, named induced pluripotent
stem cells (iPSCs), was achieved through retroviral transfec-
tion of a deﬁned set of transcription factors (Takahashi et al,
2007; Yu et al, 2007; Park et al, 2008b). To date, multiple
somatic cells from diverse adult tissues (i.e., endoderm,
mesoderm and ectoderm origins) have been successfully
reprogrammed to iPSCs, including ﬁbroblasts (Takahashi
et al, 2007; Yu et al, 2007; Park et al, 2008b), blood (Loh
et al, 2009), neural progenitors (Eminli et al, 2008) and fully
differentiated lymphocytes (Hanna et al, 2008). Furthermore,
multiple strategies have been proposed as alternatives to
potentially harmful retroviruses, including drug-inducible
systems (Hockemeyer et al, 2008), virus-free transposon
mediated (Woltjen et al, 2009), recombinant proteins (Kim
et al, 2009) and miRNAs (Miyoshi et al, 2011). Finally, human-
induced pluripotent stem cells (hiPSCs) represent a unique
tool to develop cellular models for many human diseases
(Park et al, 2008a; Soldner et al, 2009).
Although current functional assays such as in-vitro differ-
entiation, teratoma formation, chimera formation germline
contribution and tetraploid complementation (Jaenisch and
Young, 2008) have conﬁrmed the pluripotency of hiPSCs
(Takahashi et al, 2007; Yu et al, 2007; Park et al, 2008b), there
might still be signiﬁcant differences when comparedwith their
natural hESC counterparts. For instance, hiPSCs have been
shown to differentiate in a less efﬁcient manner than hESCs
(Feng et al, 2010; Hu et al, 2010). Consequently, an extensive
molecular characterization to address differences and simila-
rities between these two pluripotent cell lines seems to be a
prerequisite before any clinical application is conducted.
Despite that great efforts have been made to address how
similar hESCs and hiPSCs are, the deﬁnite answer to this
fundamental question is still the subject of active debate
(Guenther et al, 2010; Newman and Cooper, 2010; Chin et al,
2009, 2010b). Using microarray-based approaches, several
studies have reported residual levels of transcriptional
memory of the parental somatic cell line in the reprogrammed
hiPSCs (Chin et al, 2009; Marchetto et al, 2009; Ghosh et al,
2010; Ohi et al, 2011). However, it has also been shown that
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signatures due to in-vitro microenvironmental conditions
rather than a recurrent molecular signature across different
hiPS cell lines (Guenther et al, 2010; Newman and Cooper,
2010). In addition, epigenetic analyses have documented
signiﬁcant differences in the DNA methylation patterns
between hiPSCs and hESCs (Deng et al, 2009; Doi et al,
2009; Lister et al, 2009; Kim et al, 2010; Polo et al, 2010; Bock
etal,2011).Infact,thetranscriptionalmemoryofhiPSCscould
be partially explained by the incomplete DNA methylation at
the promotor regions of somatic genes (Ohi et al, 2011). Non-
coding miRNAs have an important role in the underlying
mechanisms of reprogramming (Samavarchi-Tehrani et al,
2010; Subramanyam et al, 2011) and they can replace the
ectopic expression of transcription factors to generate iPSCs
with even higher efﬁciency (Anokye-Danso et al, 2011). Thus,
miRNA proﬁles between hESCs and hiPSCs were compared
and a signature in the expression of the miR-371/372/373
cluster was found (Wilson et al, 2009). Finally, genetic
integrity was also studied and it was found that the
reprogramming process could induce several genomic
abnormalities (Mayshar et al, 2010; Hussein et al,2 0 1 1 ;
Laurent et al, 2011).
Despite intensive efforts in molecular characterization,
direct assessment of protein levels has yet to be incorporated
intotheseintegrativesystems-levelanalyses.Proteinlevelsare
tuned by intricate mechanisms of gene expression regulation
and it has recently been documented that mRNA and protein
levels poorly correlate in mouse ESCs (Lu et al, 2009).
Proteomics is, however, more labor-intensive and often lacks
the proﬁling depth that can be obtained at the transcript level.
Mass spectrometry (MS)-based proteomics is, currently, the
most powerful tool to globally proﬁle proteomes and has also
been used to study different aspects of the stem cell biology
(Swaney et al, 2009; Van Hoof et al, 2009; Rigbolt et al, 2011).
Here, we use in-depth quantitative proteomics to gain insights
into the differences and similarities in the protein content of
two hiPS cell lines (IMR90 and 4Skin), their precursor
ﬁbroblast cell lines and one hES (HES-3) cell line, all grown
and maintained under the same experimental conditions,
providing novel molecular signatures that may assist in ﬁlling
a gap in our understanding of pluripotency.
Results
Conﬁrmation of pluripotency and experimental
design
To study the degree of similarity, at the protein level, between
hiPSCs and hESCs, two MS-based proteomic experiments
using two different hiPS cell lines were conducted (Figure 1).
In Experiment 1, IMR90_iPS were compared to hESCs (HES-3)
and to the parental cell line, IMR90_Fibro. In Experiment 2,
4Skin_iPS, hESCs (HES-3) and the somatic cells, 4Skin_Fibro,
were analyzed. Both hiPS cell lines were derived through the
reprogramming of IMR90 fetal ﬁbroblasts and foreskin
ﬁbroblasts, by ectopic expression using retroviruses carrying
SOX2, OCT4, NANOG and LIN28 transgenes (Yu et al, 2007).
Upon extended culture, hiPSCs adopt a gene expression proﬁle
which more closely resembles that of the hESCs (Chin et al,
2009). For this study, the two hiPS cell lines were analyzed at
late passage. However, long-term culture conditions might
induce genomic instability (Baker et al, 2007), which might
compromise the pluripotency of these cell lines. Therefore, we
conﬁrmed the pluripotency of both hiPS cell lines by checking
the expression of known hESCs markers (e.g., OCT4,
podocalyxin and tra-1-60), karyotypic stability and in-vivo
differentiation capabilities (Supplementary Figure S1).
Characterization of hESCs (HES-3 cell line) was described
elsewhere (Chin et al, 2010a).
All the six samples were subjected for proteomic analysis
(Figure 1). Basically, proteins were extracted in a buffer
containing 8M urea and subsequently cleaved into peptides
using a double digestion with Lys-C and trypsin (Figure 1).
Metabolic labeling presents some caveats in hESCs (Van Hoof
et al, 2007) and, so far, has not been applied to hiPSCs;
whereas label-free approaches are less suitable for large
multidimensional separation-based strategies. Therefore, we
applied our in-house developed peptide labeling that uses
solid-phase extraction and triplex dimethyl labeling chemistry
(Boersema et al, 2009). Two biological replicas were con-
ducted for each experiment, where labels were swapped
between the hESCs and hiPSCs (parental ﬁbroblasts were kept
constant; Figure 1). In order to ensure maximal protein
identiﬁcation, we reduced sample complexity by a strong
cation exchange (SCX) chromatography. Subsequently,
Experiment 1 was analyzed by high-resolution LC-MS/MS
with electron transfer dissociation (ETD) as well as collision-
induced dissociation (CID) for peptide sequencing. Experi-
ment 2 was analyzed with a data-dependent decision tree
using higher-energy collision dissociation (HCD) and ETD
with either Orbitrap or linear ion trap readout (Frese et al,
2011). MS intensities of the ‘light’,‘intermediate’ and ‘heavy’
peaks accurately reﬂect the relative abundance of peptides in
the three cell types (Figure 1).
In-depth quantitative proteomic analysis of hESCs,
hiPSCs and ﬁbroblasts
An overview of the proteomic results is presented in
Supplementary Table S1. Brieﬂy, a total of 348 LC-MS/MS
analyses (including technical and biological replicates) were
performed leading to 4551920 MS/MS sequencing events
(cumulative value of CID, HCD and ETD spectra). We
conﬁdently identiﬁed 1593446 peptide spectrum matches at
a peptide false discovery rate (FDR) below 1% (Mascot Ion
Score420). In Experiment 1 (IMR90), a total of 6873 unique
protein groupswere identiﬁed (3994 in common betweenboth
biologicalexperiments;SupplementaryTableS2).Ontheother
hand, Experiment 2 (4Skin) consists of 8548 unique protein
groups (5516 identiﬁed in both biological replicas; Supple-
mentary Table S3). Combining all the data sets, we identiﬁed
10628 unique protein groups (3001 proteins were identiﬁed at
the intersection of all four data sets). Most importantly, the
vast majority of the proteins in our data set (80–90%) were
identiﬁed on the basis of at least two unique peptides with an
average of 9±15 peptides per protein (Supplementary Figures
S2 and S3). To the best of our knowledge, the coverage
obtained in this study represents the largest achieved by any
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studies are biased toward the detection of highly expressed
genes; nevertheless, our data set includes numerous proteins
known to be of low abundance in mammalian cells. We
classiﬁed, by protein class, all the 10628 identiﬁed proteins
(7631 contained ofﬁcial gene symbols with functional annota-
tion) and found 649 transcription factors, 247 kinases (48% of
the putative human kinome (Manning et al, 2002)), and
proteins that are difﬁcult to detect by MS, such as membrane
proteins (1494 proteins were predicted by TMHMM to contain
transmembrane helices). Interestingly, we also conﬁrmed the
existence, at the protein level, of genes where only transcript
evidence was available (1876 proteins were annotated as
‘hypothetical’ or ‘putative uncharacterized’). Furthermore, we
compared our data set with two of the largest proteomic
analyses carried out to date in hESCs (Van Hoof et al, 2009;
Rigboltetal,2011).Remarkably,wefoundahighoverlapaswe
identiﬁed B90% of the reported proteins by these studies
(B2200 were unique to our current analysis). The transcrip-
tional circuitry involved in pluripotency is controlled bya core
of three transcription factors: SOX2 (Yuan et al, 1995; Avilion
et al, 2003), NANOG (Mitsui et al,2003) and OCT4(Niwaet al,
2000). We conﬁdently identiﬁed the protein product of these
genes and several other well-known hESC markers, such as
DNMT3B, UTF1, PODXL, GRB7 and BRIX (Adewumi et al,
2007). Taken together, these results indicate the comprehen-
siveness of our data (mammalian cells express 10000–15000
transcripts (Jongeneel et al, 2003)) and thus it can serve as a
reliable resource for those interested in the pluripotent stem
cell proteome.
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Figure 1 Experimental workﬂow and overview of the proteomic experiments performed. To characterize the proteomes of human-induced pluripotent stem cells
(hiPSCs) and human embryonic stem cells (hESCs), two MS-based experiments, using two independent hiPS cell lines, were conducted. Experiment 1 (top-left panel)
focused on hiPS_IMR90, hESCs and IMR90 fetal ﬁbroblasts (cell line used for reprogramming). Experiment 2 (top-right panel) focused on hiPS_4Skin, hESCs and
parental 4Skin fetal ﬁbroblasts. Proteins were extracted and digested with Lys-C and trypsin. Peptides were labeled using triplex dimethyl chemistry, equally mixed and
prefractionated by using strong cation exchange (SCX). Two biological replicas were performed for each experiment, where labels were swapped between hiPSCs and
hESCs. SCX fractions were analyzed by high-resolution LC-MS/MS. Experiment 1 was analyzed with an LTQ Orbitrap XL using both CID and ETD fragmentations,
whereasExperiment2wasanalyzedwithanLTQOrbitrapVelosusingadata-dependentdecisiontree(DDDT)usingHCDandETD.Thepeakintensitiesoftheidentiﬁed
peptides reﬂect their relative abundance in the samples (bottom panel).
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3537 of which were found in common between the two
biological replicas (Supplementary Table S2). In the sameway,
quantitative measurements for 7154 proteins were obtained in
Experiment 2, where 4718 proteins were measured in the two
biological replicas (Supplementary Table S3). We further
focused on the 2683 proteins conﬁdently quantiﬁed in all our
experiments and data sets. The analysis of variability in our
technical (Supplementary Figure S4) and biological (Supple-
mentary Figure S5) replicas demonstrated high quantiﬁcation
accuracy and reproducible proteomic measurements for both
experiments with Pearson correlation factors between 0.84
and 0.96. Remarkably, B85% of our protein ratios showed
o35% variability (Supplementary Figures S6D, S7D, S8D and
S9D). Of note, we obtained accurate measurements for
proteins changing in abundance more than 100-fold. Further-
more,usingtheextractedionchromatogramsofthethreemost
abundant peptides per protein (Grossmann et al, 2010), we
estimated the absolute abundance of the identiﬁed proteins
within the samples spanning six orders of magnitude
(Supplementary Tables S2 and S3).
High similarity in the proteomes of hESCs
and hiPSCs
Besides the fact that both hiPSCs and hESCs are pluripotent, it
is still not clear how similar both cell lines are at the proteome
level. Thus, we compared the protein levels of hESCs and
hiPSCs and found a very high degree of similarity. In Figure 2,
the absolute protein abundance (log10 scale) is plotted against
the relative protein ratios (log2 scale) for the hESC/IMR90_iPS
(Figure 2A) and hESC/4Skin_iPS (Figure 2B) comparisons.
The vast majority of the proteins showed minor or no changes
between hiPSCs and hESCs (as seen in the histograms of
frequencies). As expected, pluripotency markers including
SOX2, NANOG, OCT4, LIN28 and SALL4 were found in almost
identical levels between hESCs and hiPSCs in both experi-
ments. We then sought to deﬁne those proteins that
differentially expressed between hESCs and hiPSCs. For this
purpose, we used the signiﬁcance analysis of microarrays
(SAMs) test (Tusher et al, 2001): a commonly used statistical
test in transcriptomic studies (see Materials and methods
section). SAM has been recently shown to be applicable for
quantitative proteomic data sets as well (Roxas and Li, 2008)
and is particularly useful because it provides an estimation of
FDRs for a deﬁned set of signiﬁcant changes. Only those
proteins quantiﬁed in both experiments (i.e., IMR90 and
4Skin) and in both biological replicas were subjected to
statistical analysis using SAM (i.e., 2683 proteins). Figure 3A
shows the log2 ratios for the hESCs/hiPSCs comparisons of the
2683 ‘conﬁdently’ quantiﬁed proteins represented as a
heatmap plot. After SAM analysis, we found 58 proteins
signiﬁcantly regulated (FDR¼1.27%, Supplementary Figure
S10A) between the two hiPS cell lines and the hESCs: 46
proteins hESCs4hiPSCs and 12 proteins hESCsohiPSCs
(Figure 3B and Supplementary Table S4).
Next, we tested whether the proteins differentially
expressed between hiPSCs and hESCs were functionally
linked. To this end, we used GO enrichment analyses using
all the 10658 identiﬁed proteins in this study as the back-
ground data set (see Materials and methods section). The 46
proteins upregulated in hESCs were enriched (Po0.05,
binomial test) in GO terms related to antigen processing
(e.g., b-2 microglobulin (B2M), TABP) and metabolism of
amino acids (e.g., SDHB, ACOX1) and lipids (e.g., APOL2,
SOAT1) among others (Supplementary Figure S11A). On the
other hand, the 12 proteins that we found highly expressed in
hiPSCs were mainly related to cell-adhesion and ectoderm and
mesoderm development (e.g., VCAN, COL4A1, CDH2;
Po0.05, binomial test; Supplementary Figure S11B). Taken
together, our results indicate that the reprogramming process
remodeledtheproteomeofbothﬁbroblastcelllinestoaproﬁle
that closely resembles the pluripotent hESCs proteome: 97.8%
of the ‘conﬁdently’ quantiﬁed proteins (i.e., 2683 proteins)
showed nonsigniﬁcant changes. Nevertheless, a small fraction
oftheirproteomes,58proteins(2.2%),wasfoundsigniﬁcantly
changing between hiPSCs and hESCs. Functional analyses on
this subset of proteins revealed enrichment in certain
biological processes, including cell communication and
immune system.
Profound differences in the proteomes of hiPSCs
and their parental ﬁbroblast cell lines
The inclusion of the two parental ﬁbroblast cell lines in our
analysis allowed us to study changes in the proteome at both
the starting and end points of the reprogramming process.
As expected, this comparison revealed completely different
proteomes: the vast majority of the proteins showed differ-
ential expression between the parental ﬁbroblasts and the
reprogrammed pluripotent cells (Figure 2). We observed a
remarkable number of highly abundant proteins displaying
very extreme ratios in the ﬁbroblasts (more than 100-fold in
many cases). Some of these proteins corresponded to
ﬁbroblast markers, such as VIM, COL1A1, COL1A2 and
THBS1, which were absent in the hiPSCs. On the other hand,
we also conﬁrmed the higher expression in the hiPSCs of
known pluripotency markers such as SOX2, NANOG, OCT4,
LIN28andSALL4.UsingtheSAMstatisticalanalysis,wefound
943 proteins signiﬁcantly enriched in ﬁbroblasts and 1029
proteins with higher levels in the reprogrammed cells
(FDR¼1.1%, Supplementary Figure S10B; Figure 3C and D
and Supplementary Table S4). When we looked at the GO
terms associated with these proteins, we found that the
ﬁbroblasts were enriched in terms related to transport,
endocytosis, exocytosis and metabolism (Supplementary
Figure S11C). On the other hand, the proteins enriched in
hiPSCs were enriched in numerous GO categories spanning
different biological processes such asnucleicacid metabolism,
chromatin organization and cell cycle (Supplementary Figure
S11D). To further investigate this, we subjected all the hiPSCs
and ﬁbroblast-speciﬁc proteins to String analysis (Snel et al,
2000), a bioinformatic tool that reconstructs protein networks
based on different features like co-expression of genes,
physical interactions and co-citation. Strikingly, we obtained
hyper-connected protein networks for both sets of proteins
(Supplementary Figure S12). The majority of the proteins
showed multiple functional connections with other members,
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4 Molecular Systems Biology 2011 & 2011 EMBO and Macmillan Publishers LimitedFigure 2 Quantitative proteomic comparisons of hESCs, two hiPSCs and their precursor ﬁbroblast cell lines. Protein abundances (Grossmann et al, 2010) are plotted
againstprotein ratiosfor the hESCs/IMR90_iPS(A),hESCs/4Skin_iPS (B),IMR90_Fibro/IMR90_iPS (C)and4Skin_Fibro/4Skin_iPS (D)comparisons. Thesizeof the
spotreﬂects the numberofunique peptides usedtocalculate the proteinratio.Thecolor codereﬂects thevariability (i.e., relative standarddeviation) ofthe peptide ratios
for each protein. On top, the histograms of frequencies show the density of proteins in each analysis using a bin size of 0.25 (log2). Some of the proteins that are
discussed in the text are shown in the plots. NA, not applicable.
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links was clearly observed in both analyses. Therefore, we
reasoned that the observed protein networks may constitute
the protein backbone that controls pluripotent cells and fully
differentiated ﬁbroblast cells.
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Figure 3 Proteome differences between hESCs, hiPSCs and their precursor ﬁbroblasts. 2683 proteins were quantiﬁed in the four data sets: IMR90 and 4Skin
experiments (Biological replicas 1 and 2). Relative protein abundances are represented as heatmaps for hESCs/hiPSCs (A) and ﬁbroblasts/hiPSCs (C) comparisons.
Usingsigniﬁcance analysisofmicroarrays (SAM;Tusher etal,2001; RoxasandLi,2008), 58 proteins(2.2%) were found signiﬁcantlyregulated betweenhESCs/hiPSCs
(B) and 1927 (73.4%) between ﬁbroblasts/hiPSCs (D). The ﬁgure was created using the MultiExperiment Viewer software (Saeed et al, 2006). Red and green colors
indicate upregulated and downregulated events, respectively. Genes were further grouped using hierarchical clustering (distance metric was Cosine correlation and
linkage method was average).
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in our study were a consequence of transcriptional or
translational regulation, we performed paired genome-wide
gene expression analyses on the same six samples that were
used for the proteomic proﬁling (Supplementary Methods).
Overall, we observed a good correlation between mRNA and
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Figure4 TranscriptlevelsofthedifferentiallyexpressedproteinsbetweenhiPSCsandhESCs.ThemRNAlevelsoftheidentiﬁedproteinsweremeasuredonthesame
samples that were used for the proteomic analyses using microarrays (Affymetrix platform). Gene symbols were used to correlate the measurements from both
approaches.Theﬁgureshowsthe transcriptlevelsforallthesigniﬁcantlyregulatedproteinsfoundforhESCs4hiPSCs(A),hESCsohiPSCs(B),ﬁbroblasts4hiPSCs(C)an d
ﬁbroblastsohiPSCs (D). Protein and mRNA ratios were calculated as the average of the four measurements obtained (IMR90 and 4Skin experiments with two biological
replicas each). The corresponding error bars (standard deviations) are shown for each value (error bars in C and D were omitted for a better visualization of the ﬁgure).
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the transcript levels of the regulated proteins, we found a
remarkable agreement (Figure 4). In the hESC/hiPSC compar-
ison, most of the differential proteins were accompanied by a
change in the mRNA levels in the same direction (Figure 4A
and B). The ﬁbroblast/hiPSC comparison showed the same
trend, where most of the genes regulated between these two
cell lines were affected at the protein and mRNA levels (Figure
4C and D). These results further authenticated the proteomic
measurements and implied a high degree of control at the
transcriptional level. Nevertheless, numerous genes were
found uncorrelated highlighting the necessity of complement-
ing transcriptomic-based approaches with proteomics.
Discussion
Since the discovery in 2006 that somatic cells can be
reprogrammed to an embryonic-like state (Takahashi and
Yamanaka, 2006), a fundamental question remains unan-
swered, i.e., are hiPSCs equivalent to hESCs, their natural
counterparts?Thisisespeciallyrelevantasgeneticdefectsmay
affect hiPSCs during differentiation and/or transplantation
(Hanna et al, 2010). The conventional procedure to evaluate
the pluripotency of iPSCs is based on biological assays for
developmental potency. However, the tetraploid complemen-
tation assay, which is considered the gold standard test for
pluripotency, is restricted to murine cell lines. Accordingly,
hiPSCsneed tobeexaminedextensivelyatthemolecularlevel.
This allows the characterization of hiPSCs on the basis of
quantitative measurements, which, at the same time, will
increase our knowledge on the underlying mechanisms of
pluripotency and self-renewal. In the last few years, several
studies have reported the analysis of DNA methylation status,
histone modiﬁcation patterns, coding mRNA and non-coding
miRNA expression patterns in both hiPSCs and hESCs. The
conclusions derived from such studies are still uncertain, and
the presence of a recurrent molecular signature from the
parental cell line as a consequence of incomplete reprogram-
ming (i.e., epigenetic memory) is currently being debated.
However, all the aforementioned levels of gene expression
regulation function in an orchestrated manner to tune the
actual molecular effectors of cells: proteins. Here, we have
compared the proteomes of two different hiPS cell lines, their
corresponding somatic cells and one hES cell line.
Facedwith thechallengesoftheenormousdynamicrangeof
proteins in mammalian cells, we extensively fractionated the
samples using an SCX-based approach. This allowed us to
separate peptides based on their charge state, which subse-
quently were sequenced using targeted fragmentation
schemes (i.e., CID, ETD, HCD) to enhance peptide identiﬁca-
tion (Frese et al, 2011). Using this approach, we achieved the
identiﬁcation of one the largest proteome coverage in
pluripotent cells and somatic cells, spanning six orders of
magnitude in protein abundance (Figure 2, Supplementary
Tables S2 and S3). The 50 most abundant proteins consisted of
cytoskeleton (e.g., ACT1, ACTBL2, TUBB2A), chaperones
(e.g., HSPA90AB1, HSPA8, HSPA2), ribosomal (e.g., RPS27A,
HNRPC) and histones (e.g., HIST1H4A, HIST1H2AB), the
latter group likely reﬂecting the high nucleus/cytoplasm ratio
of pluripotent stem cells (Thomson et al, 1998). On the other
hand, among the less abundant, we found numerous
transcription factors(e.g.,DMTF1, BTBD1,ZNF316),signaling
molecules and regulatory proteins (e.g., EFNB2, SOCS7,
STK35). Most importantly, proteins known to be associated
with pluripotency and self-renewal such as SOX2, NANOG,
OCT4, LIN28 and SALL4 were found to have expression levels
in the middle range (i.e., B1000 times less abundant than the
structural components), which conﬁrms the importance of
their functions in these cell. Given the fact that mRNA levels
poorly predict protein translation rates (Schwanhausser et al,
2011), our data set may be highly valuable for those
applications such as FACS and RNAi screenings, in which
knowing the absolute levels of proteins could determine the
success of the experiment (van der Flier et al, 2009).
The use of cost-effective dimethyl isotopes in our workﬂow
allowed us to accurately quantify relative protein changes
between hESCs, hiPSCs and their parental ﬁbroblast cell lines.
Furthermore, the overall good correlation with the mRNA
levels (obtained from paired microarray analyses) validated
the reliability of our proteomic measurements. The compar-
ison of two different hiPS cell lines with the hESCs conﬁrmed,
at the protein level, that the reprogramming process success-
fully activated the expression of pluripotency genes and
repressed those related to terminally differentiated ﬁbroblasts.
The proteomes of hiPSCs and hESCs were found to be very
similar, where 97.8% of the proteins displayed nonsigniﬁcant
changes. Nevertheless, a small subset of proteins (58) was
found differentially expressed in common in the two experi-
ments conducted (Figure 3B and Supplementary Table S4),
among them are several components of the immune system.
Our results showed that iPSCs have reduced levels (less than
3-fold) of two proteins that are essential for the cell-surface
expression of HLA class I and correct antigen presentation:
B2M and tapasin (TAPBP). In agreement with our results,
it has been shown that the reprogramming process might
downregulate, through epigenetic mechanisms, MHC and
processing molecules (Sua ´rez-Alvarez et al, 2010). Further
experimentation will be necessary to ﬁnd out if these ﬁndings
mayimpacttheimmunogenicityofhiPSCs,but,interestingly,a
recent report has described immune rejection on autologous
transplanted murine iPSCs (Zhao et al, 2011).
Several evidences point out that epigenetic mechanisms
underlie some of the differences found in transcriptomic
studies between hiPSCs and hESCs, reviewed in Hanna et al
(2010). Genome-wide maps of nucleosomes, i.e., activating
K4me3 and repressive K27me3 marks, revealed that both
pluripotent cell lines are markedly similar (Guenther et al,
2010). However, modiﬁcations in the histone tails are
reversible changes that cause local formation of heterochro-
matin, whereas DNA methylation leads to long-term repres-
sion (Berger, 2007). Analyses of the ‘DNA methylome’ at
different base pair resolutions have shown manifest differ-
ences between hiPSCs and hESCs, pointing out that the
reprogramming process could fail in repressing certain genes
from the donor cells (epigenetic memory). Moreover, aberrant
methylation patterns acquired during reprogramming (epige-
neticmutation)havebeendescribed(Listeretal,2011).Hence,
we checked, in the parental cell lines, the levels of the 12
proteins enriched in hiPSCs. Only one protein, the transferrin
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ﬁbroblasts, which thereby may be explained by incomplete
repressionofsomaticgenesduringreprogramming(CDH2and
COL4A1 were also found highly expressed in the IMR90
ﬁbroblasts, but not in the 4Skin cell line). Nevertheless, the
remaining proteins showed a lower expression in the
ﬁbroblasts when compared with the reprogrammed hiPSCs.
On the basis of the transcriptomic proﬁling, several groups
have reported that hiPSCs can be distinguished from hESCs by
the presence of a recurrent molecular signature (Chin et al,
2009; Marchetto et al, 2009; Ghosh et al, 2010). A more recent
study that includes a signiﬁcant higher number of cell lines
indicated that gene expression programs in hESCs and hiPSCs
partially overlapped, although there was a signiﬁcant differ-
ence on average hES and hiPS cell lines (Bock et al, 2011).
Owing to the relatively low throughput of MS-based proteo-
mics when compared with other ‘-omics’, our study was
limited to two different hiPS cell lines, i.e., IMR90_iPS and
4Skin_iPS. Though, we found 12 proteins consistently
enriched in hiPSCs and 46 proteins in hESCs (Figure 3 and
SupplementaryTableS4).Thismaybeexplainedbythesimilar
nature of our hiPS cell lines: they are both retroviral
reprogrammed (Yu et al, 2007), have mesoderm origin and
were cultured at late passage, which altogether could
contribute to reduce noise from the analysis (Bock et al,
2011). To further investigate these ﬁndings, we compared our
listofdifferentialproteinswiththetranscriptlistsderivedfrom
several independent analyses (Yu et al, 2007; Maherali et al,
2008; Chin et al, 2009; Guenther et al, 2010). These studies
include a broad spectrum of different hiPSCs: alternative
reprogramming methods, different somatic origins and low
passage cultures. The comparisons showed some genes in
common with the differential transcripts published by Yu et al
(2007): 12/58 (e.g., CDH2, TFRC, RRM2 ACAT1, CAPG,
SDR39U1) and by Maherali et al (2008): 10/58 (e.g., DCXR,
RCN3, CDH2, SLC38A2, ACOX1, HSPA2). Nonetheless, the
overlapwasfoundnotsigniﬁcant(Fishertest,P40.05)andwe
did not ﬁnd any regulated gene common to all the studies.
Consequently, our results are in line with the emerging idea
that differences between hiPSCs and hESCs rather reﬂect
experimental conditions than a consistent molecular signa-
ture. As expected, the comparison of both hiPS cell lines with
their somatic donor ﬁbroblast cells showed massive differ-
ences in their proteomes. Bioinformatics analyses on the
differentially expressed proteins between these cell lines
disclosed functionally interconnected protein networks in
the hiPSCs and ﬁbroblasts (Figure 3). The protein network in
hiPSCs is especially relevant, as it may constitute the protein
coreregulatingpluripotency.Interestingly,withinthisnetwork
we found many proteins known to interact with SOX2,
NANOG and OCT4 in hESCs (Wang et al, 2006; Mallanna
et al, 2010; Pardo et al, 2010; van den Berg et al, 2010) such as
Requiem, PRC1, Wdr3b and P66b and NAC1. Furthermore,
numerous proteins present in this network are also target
genes of SOX2, NANOG and OCT4, i.e., the molecularcircuitry
governing pluripotency (Boyer et al, 2005), including SMAR-
CAD1, RIF1, ARID1B, DPPA4 and TLE3.
This study constitutes an invaluable resource for the
stem cell community by adding an essential layer, the
protein content, to the systems biology view of pluripotency,
highlighting the molecular similarities between these pluripo-
tent cell lines. Therefore, it is our hope that our data will serve
as a platform for future investigations, which more targeted
experimentation might reveal.
Materials and methods
Culture of hiPSCs
Induced pluripotent stem cell lines IMR90_iPS and 4Skin_iPS were
cultured in Matrigel (Becton Dickinson)-coated dishes, supplemented
with mTeSR1 media (Stem Cells Technologies) and passaged every
7 days. Brieﬂy, the cells were washed once with phosphate-buffered
saline (PBS; Gibco) before enzymatic treatment with dipase (Chemi-
con) for B3min. After neutralization with media, the cells were
triturated into small clumps or single cells and seeded onto new
Matrigel-coated at a split ratioof 1:3 to 1:8. Thecells were incubated at
371Ci n5 %C O 2 incubator.
Characterization of pluripotency
Flow cytometry analysis (FACS)
The expression levels of the pluripotent markers Oct-4, podocalyxin
and Tra-1-60 in iPSC populations were assessed by immunoﬂuores-
cence using ﬂow cytometry. Cells were harvested as a single-cell
suspensions using 0.25% trypsin–EDTA (Gibco), ﬁxed and permeabi-
lized (Caltag Laboratories) before incubation with a mouse mono-
clonal antibody to Oct-4 (1:20, Santa Cruz), podocalyxin (mAb 84,
5mg,in-house)andTra-1-60(1:50,Chemicon).Cellswerethenwashed
with 1% BSA/PBS, and incubated in the dark with goat a-mouse
antibody FITC-conjugated (DAKO) at 1:500 dilution. After incubation,
thecellswerewashedandresuspendedin1%BSA/PBSforanalysison
a FACScan (Becton Dickinson FACS Calibur). All incubations were
performed at room temperature for 15min. For the negative control,
cells were stained with the appropriate isotype control.
Staining of hESC for markers
Staining of iPSC was carried out by incubating the cells with ﬁxative
Reagent A (Caltag Laboratories)for 1h, before blocking with 3% BSA/
PBS for another hour. After washing with 0.1% Triton/PBS, the cells
were incubated with antibodies to Oct-4 (Santa Cruz), SSEA-4 (DHSB)
and Tra-1-60 (Chemicon) for 1h. The detection of bound antibodies to
the pluripotent markers was visualized using DAKO goat a-mouse
antibody conjugated with PE (diluted 1:500).
Karyotypic stability
Karyotyping analysis was performed by the Cytogenetics Laboratories
at the Department of Obstetrics and Gynaecology, KK Women’s and
Children’s Hospital. Cell samples were incubated with BrdU/colcemid
(reagent from hospital) for 16h in 371C, 5% CO2 incubator.
In-vivo differentiation assay, SCID mice model and
teratoma analysis
Induced PSCs were harvested by collagenase (Sigma) treatment and
approximately 4–5 10
6 cells were injected with a sterile 22G needle
into the rear leg muscle of 4-week-old female SCID mice. Mice that
developed tumors approximately 9–10 weeks after injection were
killed and the tumors were dissected and ﬁxed in 10% formalin.
Tumors were embedded in parafﬁn, sectioned and examined
histologically after hematoxylin and eosin staining.
Sample preparation for MS
Cells (i.e., IMR90_iPS, 4Skin_iPS, hESCs and IMR90 and 4Skin
ﬁbroblasts) were harvested by centrifugation at 2500g for 10min at
41C. Cell lysis was performed in a buffer containing 8M urea, 2M
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protease and phosphatase inhibitors (Roche). Proteins (B1mg) were
ﬁrst reduced/alkylated and digested for 4h with Lys-C. The mixture
was then diluted 4-fold to 2M urea and digested overnight with
trypsin. Digestion was quenched by acidiﬁcation with formic acid
(ﬁnal concentration 2%). Resulting peptides were then chemically
labeled with stable isotope dimethyl labeling as described previously
(Boersema et al, 2009). Brieﬂy, IMR90_iPS and 4Skin_iPS peptides
were labeled with a mixture of formaldehyde-H2 and sodium
cyanoborohydride (‘light’ reagent). For hESCs and IMR90 and 4Skin
ﬁbroblast cells, formaldehyde-D2 with cyanoborohydride (‘intermedi-
ate’ reagent) and
13C-D2-formaldehyde with cyanoborodeuteride
(‘heavy’reagent) wereusedrespectively. In a secondbiologicalreplica
experiment, hESC and hiPSC reagents were swapped, whereas
‘heavy’-IMR90/4Skin ﬁbroblast was kept constant. The ‘light’,
‘intermediate’ and ‘heavy’ dimethyl-labeled samples were mixed in
1:1:1 ratio based on total peptide amount, which was determined by
running an aliquot of the labeled samples on a regular LC-MS/MS run
and comparing overall peptide signal intensities.
Before the mass spectrometic analysis, both replicates were
fractionated using SCX systems. For Experiment 1, peptides were
fractionated as described elsewhere (Helbig et al, 2010). The SCX
system consisted of an Agilent 1100 HPLC system (Agilent Technolo-
gies, Waldbronn, Germany) with two C18 Opti-Lynx (Optimized
Technologies, OR) trapping cartridges and a polysulfoethyl A SCX
column (PolyLC, Columbia, MD; 200mm 2.1mm inner diameter,
5mm, 200-A ˚). The labeled peptides were dissolved in 10% FA and loaded
onto the trap columns at 100ml/min and subsequently eluted onto the
SCX column with 80% acetonitrile (ACN; Biosolve, The Netherlands)
and 0.05% FA. SCX buffer A was made of 5mM KH2PO4 (Merck,
Germany), 30% ACN and 0.05% FA, pH 2.7; SCX buffer B consisted of
350mM KCl (Merck, Germany), 5mM KH2PO4, 30% ACN and 0.05%
FA, pH 2.7. The gradient was performed as follows: 0% B for 10min,
0–85% B in 35min, 85–100% B in 6min and 100% B for 4min. A total
of 45 fractions were collected for each set and dried in a vacuum
centrifuge. The second SCX system (Pinkse et al, 2008) was performed
using a Zorbax BioSCX-Series II column (0.8-mm inner diameter 50-
mm length, 3.5mm). SCX solvent A consists of 0.05% formic acid in
20% ACN, while solvent B was 0.05% formic acid, 0.5M NaCl in 20%
ACN. The SCX salt gradient is as follows: 0–0.01min (0–2% B); 0.01–
8.01min (2–3% B); 8.01–14.01min (3–8% B); 14.01–28min (8–20%
B); 28–38min (20–40% B); 38–48min (40–90% B); 48–54min (90%
B); 54–60min (0% B). A total of 50 SCX fractions (1min each, i.e.,
50-mlelutionvolume)werecollectedanddriedinavacuumcentrifuge.
Only the second SCX system was used to fractionate lysates from
Experiment 2.
Mass spectrometric analysis
For Experiment 1, we performed nanoﬂow LC-MS/MS with an LTQ-
Orbitrap XL ETD mass spectrometer (Thermo Electron, Bremen,
Germany) coupled to an Agilent 1200 HPLC system (Agilent
Technologies). SCX fractions were dried, reconstituted in 10% FA
and delivered to a trap column (Aquat C18,5 mm (Phenomenex,
Torrance, CA); 20mm 100-mm inner diameter, packed in-house) at
5ml/min in100% solvent A (0.1M acetic acid inwater). Next, peptides
eluted from the trap column onto an analytical column (ReproSil-Pur
C18-AQ, 3mm (Dr Maisch GmbH, Ammerbuch, Germany); 40cm 50-
mm inner diameter, packed in-house) at approximately 100nl/min in a
90min or 3h gradient from 0 to 40% solvent B (0.1M acetic acid in 8:2
(v/v) ACN/water). The eluent was sprayed via distal coated emitter
tips butt-connected to the analytical column. The mass spectrometer
was operated in data-dependent mode, automatically switching
between MS and MS/MS. Full-scan MS spectra (from m/z 300 to
1500) were acquired in the Orbitrap with a resolution of 60000 at m/z
400 after accumulation to target value of 500000 in the linear ion trap.
For SCX fractions dominated by singly charged and doubly charged
peptides, the ﬁve most intense ions at a threshold above 5000 were
selected for collision-induced fragmentation in the linear ion trap at a
normalized collision energy of 35% after accumulation to a target
value of 10000. For highlycharged SCX fractions, the ﬁvemostintense
ions at a threshold of above 500 were fragmented in the linear ion trap
using electron-transfer dissociation with supplemental activation
(ETcaD) at a target value of 50000. The ETcaD reagent target value
was set to 100000 and the reaction time to 50ms.
MS analysis for Experiment 2 was performed with the same LC
gradient and conﬁguration but using an LTQ-Orbitrap Velos (Thermo
Electron). MS data were acquired with a data-dependent decision tree
method as described (Frese et al, 2011). Brieﬂy, following the survey
scan (30000 FHMW), the 10 most intense precursor ions were
subjected to HCD, ETD-ITor ETD-FT fragmentation. The choice of the
mostappropriatetechniqueforaselectedprecursorwasdeterminedby
a preprogrammed data-dependent decision tree. Essentially, doubly
charged peptides were subjected to HCD fragmentation and more
highly charged peptides were fragmented using ETD. The normalized
collision energy for HCD was set to 35%. ETD was enabled with
supplemental activation and the reaction time was set to 50ms for
doubly charged precursors.
Data processing
MS data were processed and quantiﬁed with Proteome Discoverer
(version 1.3, Thermo Electron) with standardized workﬂows. This
ensures consistent and reproducible quantiﬁcation for all samples,
avoiding possible bias introduced by manual intervention. These
workﬂows are made available as Supplementary Materials. For
Experiment 1, peptide identiﬁcation was performed with Mascot 2.3
(Matrix Science) against a concatenated forward-decoy IPI Human
database supplemented with all the frequentlyobserved contaminants
in MS (version 3.68, 174650 entries). The following parameters were
used: 50p.p.m. precursor mass tolerance, 0.5Da fragment ion
tolerance, up to 2 missed cleavages, carbamidomethyl cysteine as
ﬁxed modiﬁcation and oxidized methionine as variable modiﬁcations.
Dimethyl-based quantitation method was chosen in Proteome
Discoverer, with mass precision requirement of 2p.p.m. for con-
secutive precursor measurements. Besides, taking into account the
isotopic effect of deuterium, we applied 1min of retention time
tolerance for isotope pattern multiplets and allowed spectra with 2
missing channels to be quantiﬁed. After identiﬁcation and quantiﬁca-
tion, we combined all results originating from the same biological
replica and ﬁltered them according to very stringent peptide
acceptance criteria. These criteria include (i) mass deviations of
±5p.p.m., (ii) Mascot Ion Score of at least 20, (iii) a minimum of 7
amino-acid residues per peptide and (iv) position rank 1 in Mascot
search. As a result, we obtained peptide FDRs of 0.23 and 0.19% for
two respective biological replicas (Supplementary Table S1). Finally,
peptide ratios were then normalized against the median (log2). The
same criteria were subsequently applied to analyze Experiment 2
except for the following: 0.5Da fragment ion tolerance for ETD-IT, and
0.02Da fragment ion tolerance for both HCD and ETD-FT. Peptide
FDRs obtained for Experiment 2 were 0.56 and 0.59%, respectively.
The MS data associated with this manuscript can be downloaded
from ProteomeCommons.org under the following Tranche hash:
d/Ci8K23/EI0YIsZ7OQpxQjkHUlCdAMtiBKQT6aþ4McomzkpsxZYLn
ZYcm1vjmMhHv94w5or5jGg/6l42VgFGtFZSC0AAAAAAAAOtw¼¼.
Microarray analysis
RNA isolation
Cells were washed twice in PBS (Gibco), harvested and quantiﬁed
using the NucleoCounter (Chemometec). RNA was isolated using
TRIzol (Invitrogen)/chloroform according to manufacturer’s protocol.
RNAintheextractedaqueousphasewas concentratedbyprecipitation
with an equal volume of isopropanol at  201C overnight, and further
puriﬁed using RNeasy Mini Kit (Qiagen). Quantity of RNA was
measured by NanoDrop (Thermo Scientiﬁc) and quality evaluated by
capillary electrophoresis on QIAxcel (Qiagen).
Transcriptome analysis
Affymetrix U133 Plus 2.0 GeneChip Microarrays (Human Genome)
were used according to manufacturer’s protocol. Brieﬂy, GeneChip
30 IVT Express Kitwasused to generate labeledampliﬁedRNA(aRNA)
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subsequently hybridized onto each microarray. Intact aRNA yield
was measured by NanoDrop, and quality of intact and fragmented
aRNAevaluatedon 2% agarose gel. Hybridizations were carried out at
451C for 16h with reagents from GeneChip Hybridization, Wash, and
Stain Kit, with subsequent washing and staining of arrays automated
and preprogrammed (FS450_0001) on Fluidics Station 450. Arrays
were scanned using GeneChip Scanner 3000.
Microarray data analysis
Affymetrix Expression Console software was used to analyze scanned
image ﬁles. Arraydata were quantiﬁed and normalized using MAS5.0.
algorithm, with corresponding detection calls for each probeset
determined. Only data from probesets that (i) were ﬂagged as present
inatleastonesetofbiologicalreplicates,and(ii)possessedthehighest
summed intensities among redundant probesets—those annotated
withsimilargenenameorunigeneidentiﬁer,wereusedforsubsequent
comparison with the proteome study. Microarray data are available at
the NCBI Gene Expression Omnibus database under the accession
numbers GSE26451 and GSE26453.
Bioinformatic analysis
Protein classiﬁcation (molecular function, biological process, cellular
component and protein class) was performed using the PANTHER
classiﬁcation system (Mi et al, 2007). GO enrichment was performed
using a Binomial test as described elsewhere (Cho and Campbell,
2000), the entire list of identiﬁed proteins was used as the reference
data set. Protein and mRNA levels were combined using ofﬁcial gene
symbols (HUGO). Protein networks were created with String (Snel
et al, 2000).
Statistical analysis
Signiﬁcance analysis of microarrays (Tusher et al, 2001; Roxas and Li,
2008) was used to identify signiﬁcantly regulated proteins between
hESCs, hiPSCs and ﬁbroblasts. Only those proteins that were
quantiﬁed in both experiments (i.e., IMR90 and 4Skin) and in both
biological replicas were analyzed under statistical criteria. Overall,
log2-transformed ratios for 2683 proteins were processed by using the
MultiExperiment Viewer software (version 4.7.4) (Saeed et al, 2006).
Brieﬂy, one-class test was used (the mean value to test again was 0),
1000 permutations were chosen for a better approximation of FDR
values (Saeed et al, 2006), S0 value was selected according to the
method proposed by Tusher et al (2001) and q-values were calculated
for each protein. Delta values were manually adjusted to B1% FDR.
SAM graphs for both comparisons hESCs/hiPSCs and Fibroblasts/
hiPSCs are shown in Supplementary Figure S10. The results from the
analyses are presented in Supplementary Table S4.
Supplementary information
Supplementary information is available at the Molecular Systems
Biology website (www.nature.com/msb).
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